Acadia Pharmaceuticals (ACAD) Receivables - Net (2016 - 2026)

Acadia Pharmaceuticals has reported Receivables - Net for 11 years, with the latest figure at $135.4 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 28.0% year-over-year to $135.4 million; the trailing twelve-month figure through Mar 2026 stood at $135.4 million (up 28.0% YoY), and the FY2025 full-year result was $121.5 million, up 23.01% from the prior year.
• Receivables - Net for Q1 2026 stood at $135.4 million, up from $121.5 million in the prior quarter.
• The five-year high for Receivables - Net was $135.4 million in Q1 2026, with the low at $55.7 million in Q3 2022.
• Average Receivables - Net over 5 years is $92.3 million, with a median of $98.2 million recorded in 2024.
• Year-over-year, Receivables - Net decreased 8.18% in 2022 and jumped 66.51% in 2023.
• Tracing ACAD's Receivables - Net over 5 years: stood at $62.2 million in 2022, then jumped by 58.0% to $98.3 million in 2023, then increased by 0.48% to $98.7 million in 2024, then increased by 23.01% to $121.5 million in 2025, then climbed by 11.44% to $135.4 million in 2026.
• The last three Receivables - Net figures came in at $135.4 million (Q1 2026), $121.5 million (Q4 2025), and $115.8 million (Q3 2025), per Business Quant data.

Peer Comparison